RegentAtlantic Capital’s Yarrow Bioscience YARW Stock Holding History

RegentAtlantic Capital’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-28	Closed	-$10K	–	702
2022 Q2	$10K	Buy	+28	New	+$11.7K	﹤0.01%	675
2021 Q1	–	Sell	-4	Closed	-$24K	–	558
2020 Q4	$24K	Hold	4	–	–	﹤0.01%	499
2020 Q3	$25K	Hold	4	–	–	﹤0.01%	487
2020 Q2	$26K	Buy	+4	New	+$27.1K	﹤0.01%	473

Other funds holding YARW

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

RegentAtlantic Capital's YARW Position: Q3 2022 in Review

RegentAtlantic Capital sold out of Yarrow Bioscience (YARW) in Q3 2022, closing a stake of 28 shares — an estimated $10K sold.

RegentAtlantic Capital first reported a position in YARW in Q2 2020 and held it in 4 quarters. The position peaked at $26K in Q2 2020. 37 funds tracked by Wall St. Rank hold YARW as of Q3 2022.

RegentAtlantic Capital reported no remaining Yarrow Bioscience position as of Q3 2022 after selling out during the quarter.
RegentAtlantic Capital sold 28 Yarrow Bioscience shares in Q3 2022, an estimated $10K.
RegentAtlantic Capital first reported a position in Yarrow Bioscience in Q2 2020 and held it in 4 quarters.
RegentAtlantic Capital's Yarrow Bioscience position peaked at $26K in Q2 2020.
37 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q3 2022.

Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.